Novel therapeutic approaches include immunotherapy and targeted therapy (BRAF/MEK or KIT inhibitors), although mutation profiles differ from cutaneous melanoma, with KIT and NRAS mutations more common than BRAF [1,27]. Here, MAP2K7 is linked to cutaneous melanoma.